Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: StockDoc who wrote (14152)	7/17/2000 10:57:29 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

P II data is not published anywhere yet. P II data exist for both Trauma and Meningococcemia. Sort of assume, that data is old and you are looking for P III data. In theory, Meningoccoccemia P III results might be published in Sept. October.

To: StockDoc who wrote (14152)	7/17/2000 3:15:35 PM
From: Cacaito	Respond to of 17367

Stock Doc, please check: ncbi.nlm.nih.gov ncbi.nlm.nih.gov Trauma pIII, halted by DSMB due to futility, did not work at all. Some here believe in the fairy tale of the 50% improvement in the placebo group, the excuse given by P. Scanon in Vienna. Rk believes that not proven to work is important, important is that IT WORKS!, that is the real difference. But, it could be that the superacute models are not good for bpi and it will end up used in subacute and chronic settings (even as antiinflammatory/antitumor in some distant future, something like 10 years from now, if at all). The Cystic Fibrosis model is interesting one, it will be less expensive, it for long term use. It should be a natural partner for Genentech's Pulmozyme, but there is no movement at the clinic level. Rk, it is just the same story, now blurry (maybe clarify!)by Piper Jaffray interest in anticd11a and not in bpi. No Rush, I will wait for REAL facts.